Search research articles
Contact Us
Filters
Showing results (171-180 of 969) with videos related to
Page
of 97
Sort By:
Lupus
|
July 18, 2012
SLEDAI-2K Responder Index 50 captures 50% improvement in disease activity over 10 years
Z Touma, D D Gladman, D Ibañez, et al.
Lupus
|
June 5, 2002
The nature and outcome of infection in systemic lupus erythematosus
D D Gladman, F Hussain, D Ibañez, et al.
The Journal of Rheumatology
|
September 11, 2003
Clinically active serologically quiescent systemic lupus erythematosus
Dafna D Gladman, Naushad Hirani, Dominique Ibañez, et al.
Annals of the Rheumatic Diseases
|
September 15, 2011
Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?
Dafna D Gladman, Arane Thavaneswaran, Vinod Chandran, et al.
The Journal of Rheumatology
|
July 5, 2011
Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus?
Zahi Touma, Dafna D Gladman, Dominique Ibañez, et al.
Arthritis Care & Research
|
October 29, 2011
Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus
Murray B Urowitz, Anoja Anton, Dominique Ibanez, et al.
Lupus
|
January 15, 2011
SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation
Z Touma, M B Urowitz, D Ibañez, et al.
The Journal of Rheumatology
|
July 17, 2016
Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis
Barry J Sheane, Arane Thavaneswaran, Dafna D Gladman, et al.
Clinical and Experimental Rheumatology
|
March 23, 2000
Comparison of clinical and immunogenetic features in familial versus sporadic psoriatic arthritis
P Rahman, C T Schentag, M Beaton, et al.
The Journal of Rheumatology
|
December 1, 1994
Serologically active clinically quiescent systemic lupus erythematosus--predictors of clinical flares
B A Walz LeBlanc, D D Gladman, M B Urowitz
Page
of 97
Search research articles
Search
Showing results (171-180 of 969) with videos related to
Sort By:
Page
of 97
Lupus
|
July 18, 2012
SLEDAI-2K Responder Index 50 captures 50% improvement in disease activity over 10 years
Z Touma, D D Gladman, D Ibañez, et al.
Lupus
|
June 5, 2002
The nature and outcome of infection in systemic lupus erythematosus
D D Gladman, F Hussain, D Ibañez, et al.
The Journal of Rheumatology
|
September 11, 2003
Clinically active serologically quiescent systemic lupus erythematosus
Dafna D Gladman, Naushad Hirani, Dominique Ibañez, et al.
Annals of the Rheumatic Diseases
|
September 15, 2011
Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?
Dafna D Gladman, Arane Thavaneswaran, Vinod Chandran, et al.
The Journal of Rheumatology
|
July 5, 2011
Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus?
Zahi Touma, Dafna D Gladman, Dominique Ibañez, et al.
Arthritis Care & Research
|
October 29, 2011
Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus
Murray B Urowitz, Anoja Anton, Dominique Ibanez, et al.
Lupus
|
January 15, 2011
SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation
Z Touma, M B Urowitz, D Ibañez, et al.
The Journal of Rheumatology
|
July 17, 2016
Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis
Barry J Sheane, Arane Thavaneswaran, Dafna D Gladman, et al.
Clinical and Experimental Rheumatology
|
March 23, 2000
Comparison of clinical and immunogenetic features in familial versus sporadic psoriatic arthritis
P Rahman, C T Schentag, M Beaton, et al.
The Journal of Rheumatology
|
December 1, 1994
Serologically active clinically quiescent systemic lupus erythematosus--predictors of clinical flares
B A Walz LeBlanc, D D Gladman, M B Urowitz
Page
of 97